Skip to main content
13260917 Canada Inc. logo

13260917 Canada Inc. — Investor Relations & Filings

Ticker · MSCL TSXV Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2021-08-18 Regulatory Filings
Country CA Canada
Listing TSXV MSCL

About 13260917 Canada Inc.

www.satellos.com

13260917 Canada Inc. is the legal predecessor of Satellos Bioscience Inc., a biotechnology company specializing in regenerative medicine for degenerative muscle diseases. The company focuses on Duchenne muscular dystrophy (DMD), utilizing a proprietary scientific approach rooted in restoring muscle stem cell function. Satellos discovered that dystrophin deficiency disrupts muscle stem cell asymmetric division, hindering natural repair. Its core product development involves small molecule therapeutics, such as SAT-3247 (in Phase 2 clinical trials), designed to modulate the AAK1 protein. This modulation aims to reactivate the body's intrinsic muscle repair mechanisms, offering a novel oral treatment strategy for patients with DMD and related conditions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a Joint Development Agreement between Satellos Bioscience Inc. and NW PharmaTech Limited for the development of an oral CBD formulation. It includes company background, partnership details, and forward-looking statements. There are no financial statements, regulatory filings, voting results, or management changes reported. The document is a corporate announcement about a business development and partnership, not a financial report, regulatory filing, or other specific filing type. Therefore, it best fits the category of a general Regulatory Filing (RNS) as a miscellaneous corporate announcement that does not fit other categories.
2021-08-18 English
Other securityholders documents - English.pdf
Regulatory Filings Classification · 95% confidence The document is a Certificate of Continuance under the Canada Business Corporations Act (CBCA), certifying that the corporation continues under the CBCA with attached articles of continuance. It includes corporate name, corporation number, details about share classes, directors, and other provisions. There are no financial statements, management discussion, or earnings data. The document is a legal certification related to corporate status and governance rather than a financial report or announcement. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory filing related to corporate status and legal compliance. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is 4217 characters, which is relatively short and consistent with a certification document rather than a full report.
2021-08-18 English
Other securityholders documents - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Certificate of Amalgamation' under the Canada Business Corporations Act, certifying that a corporation resulted from an amalgamation of other corporations. It is a formal certification document related to corporate structure changes, specifically an amalgamation. There is no financial data, no mention of financial performance, no shareholder voting results, no management discussion, no earnings information, or any other financial or regulatory report content. The document is a legal certification of corporate amalgamation, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement or a regulatory filing in the sense of compliance filings. The closest fitting category is Regulatory Filings (RNS) as a fallback for miscellaneous filings that do not fit other categories, especially since it is a formal corporate legal document. The document length is short (1380 characters), and it is a certificate, not a report or announcement of a report.
2021-08-18 English
Notice.pdf
Regulatory Filings Classification · 95% confidence The document is a notice regarding a change in corporate structure due to a reverse takeover transaction involving Satellos Bioscience Inc. It references National Instrument 51-102, which governs continuous disclosure obligations in Canada, and details the transaction's effective date, parties involved, and trading symbol changes. The document does not contain financial statements or detailed financial analysis but serves as an official announcement of a corporate transaction and structural change. It is not a full annual or interim report, audit report, or earnings release. It is also not a proxy, voting result, or remuneration report. The document fits best as a Regulatory Filing (RNS) because it is a formal disclosure of a significant corporate event required by securities regulations but does not fall into more specific categories like M&A filings or capital updates since it is primarily a notice of corporate structure change under continuous disclosure rules.
2021-08-17 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is a Material Change Report Form 51-102F3, which is a regulatory filing used in Canadian securities regulation to disclose material changes in a company. The content details a reverse takeover transaction, business combination, share consolidation, financing, escrow arrangements, and changes in board and management. It includes detailed descriptions of the transaction, financing, and governance changes but does not contain financial statements or quarterly/yearly financial results. It is not an annual or interim report, earnings release, or audit report. It is a regulatory announcement about a material corporate event and related disclosures. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-08-17 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the completion of a reverse takeover transaction involving Satellos Bioscience Inc. and iCo Therapeutics Inc. It includes information about the transaction structure, share exchange ratios, financing details, escrow arrangements, conversion of promissory notes, new board appointments, stock option grants, and appointment of a new CFO. The content focuses on corporate restructuring, financing, and management changes rather than financial results or regulatory filings. There is no indication that this is a full annual or interim report, audit report, earnings release, or other financial statement. The document primarily announces the completion of a significant corporate transaction and related financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-08-17 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.